サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1767780

バイオベターの世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）

Biobetters Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 180 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.05円
バイオベターの世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年07月09日
発行: Persistence Market Research
ページ情報: 英文 180 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

重要な知見

  • バイオベターの市場規模：711億米ドル（2025年）
  • 予測される市場金額：1,230億米ドル（2032年）
  • 世界市場の成長率：8.2%（2025年～2032年のCAGR）

バイオベター市場 - レポート範囲

バイオベターは、既存の生物学的製剤を改良したもので、オリジナルの生物学的製剤やバイオシミラーと比較して、有効性、安全性、患者のコンプライアンスを高めるように設計されています。バイオベター市場は、製薬企業、バイオテクノロジー企業、医療提供者に、がん、自己免疫疾患、感染症などのさまざまな慢性疾患や複雑な疾患に対する先進の治療オプションを提供します。市場成長の促進要因は、標的治療に対する需要の増加、タンパク質工学とドラッグデリバリー技術の進歩、慢性疾患の世界的な流行です。

市場成長の促進要因

世界のバイオベター市場は、臨床プロファイルが改良され免疫原性が低下した生物学的製剤の採用が増加するなど、複数の要因によって推進されています。既存の生物学的製剤の安全性と有効性を高めることに重点を置いた研究開発への投資の拡大が、市場の拡大に大きく寄与しています。さらに、ブロックバスター生物学的製剤の特許切れが、より優れた性能を持つ代替品としてのバイオベターの開発を推進しています。従来の生物学的製剤やバイオシミラーよりもバイオベターが優れているという認識が医療従事者や患者の間で高まっていることも、市場成長をさらに後押ししています。

市場抑制要因

有望な成長見通しにもかかわらず、バイオベター市場は、高い開発コスト、複雑な規制経路、長い承認プロセスに関する課題に直面しています。先発品の生物製剤よりも安全性と有効性が向上していることを証明するためには、大規模な臨床試験が必要であり、メーカーに対する経済的・時間的負担が大きいです。さらに、各地域における価格圧力と償還の不確実性が、特にコストが重視される新興経済国での市場浸透を制限する可能性があります。

市場機会

バイオベター市場は、先進のタンパク質修飾技術、新しいドラッグデリバリーシステム、バイオマーカーに基づく患者層別化などの技術革新によって大きな成長機会がもたらされます。新たな治療領域や適応症へのバイオベターの拡大は、多様化と収益の拡大の可能性をもたらします。製薬企業、学術機関、開発業務受託機関の共同研究はイノベーションを促進し、製品開発を加速します。さらに、個別化医療アプローチの採用が増加しており、特定の患者のニーズに合わせたバイオベターの需要が高まっています。

当レポートでは、世界のバイオベター市場について調査し、成長促進要因、動向、機会、課題などの市場力学の詳細な分析を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主要動向
  • マクロ経済要因
    • 世界の部門の見通し
    • 世界のGDP成長の見通し
  • COVID-19の影響の分析
  • 予測要因 - 関連性と影響

第3章 付加価値考察

  • 規制情勢
  • 製品採用分析
  • バリューチェーン分析
  • 主な取引と合併
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 世界のバイオベター市場の見通し

  • 主なハイライト
    • 市場規模と前年比成長
    • 絶対的収益機会
  • 市場規模の分析と予測
    • 市場規模の実績の分析（2019年～2024年）
    • 現在の市場規模の分析と予測（2025年～2032年）
  • 世界のバイオベター市場の見通し：製品タイプ
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：製品タイプ別（2019年～2024年）
    • 現在の市場規模の分析と予測：製品タイプ別（2025年～2032年）
      • エリスロポエチンバイオベター
      • G-CSFバイオベター
      • インターフェロンバイオベター
      • インスリンバイオベター
      • モノクローナル抗体バイオベター
      • 抗血友病因子
      • その他
    • 市場の魅力分析：製品タイプ
  • 世界のバイオベター市場の見通し：適応症
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：適応症別（2019年～2024年）
    • 現在の市場規模の分析と予測：適応症別（2025年～2032年）
      • 糖尿病
      • がん
      • 腎臓病
      • 神経変性疾患
      • 遺伝性疾患（血友病）
      • その他
    • 市場の魅力分析：適応症
  • 世界のバイオベター市場の見通し：投与経路
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：投与経路別（2019年～2024年）
    • 現在の市場規模の分析と予測：投与経路別（2025年～2032年）
      • 皮下
      • 静脈
    • 市場の魅力分析：投与経路
  • 世界のバイオベター市場の見通し：流通チャネル
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：流通チャネル別（2019年～2024年）
    • 現在の市場規模の分析と予測：流通チャネル別（2025年～2032年）
      • 病院薬局
      • 小売薬局
      • オンライン薬局
    • 市場の魅力分析：流通チャネル

第5章 世界のバイオベター市場の見通し：地域

  • 主なハイライト
  • 市場規模の実績の分析：地域別（2019年～2024年）
  • 現在の市場規模の分析と予測：地域別（2025年～2032年）
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米のバイオベター市場の見通し

第7章 欧州のバイオベター市場の見通し

第8章 東アジアのバイオベター市場の見通し

第9章 南アジア・オセアニアのバイオベター市場の見通し

第10章 ラテンアメリカのバイオベター市場の見通し

第11章 中東・アフリカのバイオベター市場の見通し

第12章 競合情勢

  • 市場シェア分析（2025年）
  • 市場構造
    • 競合強度マップ：市場別
    • 競合ダッシュボード
  • 企業プロファイル（詳細 - 概要、財務、戦略、近年の発展）
    • Amgen Inc.
    • F.Hoffmann-La Roche AG
    • Merck & Co. Inc.
    • Sanofi SA
    • SERVIER
    • Porton Biopharma Limited
    • Eli Lily and Company
    • Novo Nordisk A/S
    • Biogen Inc.
    • CSL Behring GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Celltrion Healthcare Co., Ltd.

第13章 付録

目次
Product Code: PMRREP21151

Persistence Market Research has recently released a comprehensive report on the global biobetters market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global biobetters market from 2025 to 2032.

Key Insights:

  • Biobetters Market Size (2025E): USD 71.1 Billion
  • Projected Market Value (2032F): USD 123.0 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 8.2%

Biobetters Market - Report Scope:

Biobetters are improved versions of existing biologic drugs, engineered to enhance efficacy, safety, and patient compliance compared to original biologics or biosimilars. The biobetters market caters to pharmaceutical companies, biotechnology firms, and healthcare providers by offering advanced therapeutic options for various chronic and complex diseases, including oncology, autoimmune disorders, and infectious diseases. Market growth is driven by increasing demand for targeted therapies, advancements in protein engineering and drug delivery technologies, and growing prevalence of chronic illnesses worldwide.

Market Growth Drivers:

The global biobetters market is propelled by several key factors, including rising adoption of biologic therapies with improved clinical profiles and reduced immunogenicity. Growing investments in research and development activities focusing on enhancing existing biologic drugs' safety and efficacy contribute significantly to market expansion. Additionally, patent expirations of blockbuster biologics are fueling the development of biobetters as alternatives with better performance characteristics. Increasing awareness among healthcare professionals and patients about the benefits of biobetters over traditional biologics and biosimilars further supports market growth.

Market Restraints:

Despite promising growth prospects, the biobetters market faces challenges related to high development costs, complex regulatory pathways, and lengthy approval processes. The need for extensive clinical trials to demonstrate improved safety and efficacy over originator biologics imposes significant financial and time burdens on manufacturers. Furthermore, pricing pressures and reimbursement uncertainties in various regions may limit market penetration, particularly in cost-sensitive emerging economies.

Market Opportunities:

The biobetters market presents significant growth opportunities driven by technological innovations such as advanced protein modification techniques, novel drug delivery systems, and biomarker-based patient stratification. Expansion of biobetters into new therapeutic areas and indications offers potential for diversification and revenue growth. Collaborations between pharmaceutical companies, academic institutions, and contract research organizations foster innovation and accelerate product development. Moreover, increasing adoption of personalized medicine approaches amplifies demand for biobetters tailored to specific patient needs.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the biobetters market globally?
  • Which therapeutic areas and drug types are driving biobetter adoption across healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the biobetters market?
  • Who are the key players contributing to the biobetters market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global biobetters market?

Competitive Intelligence and Business Strategy:

These companies invest heavily in R&D to develop next-generation biologics with enhanced therapeutic profiles. Partnerships with biotechnology firms and contract development organizations facilitate efficient product development and market entry. Emphasis on clinical trials, regulatory compliance, and patient-centric approaches fosters market growth and improves patient outcomes in the evolving biobetters landscape.

Key Companies Profiled:

  • Amgen Inc.
  • F.Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Sanofi SA
  • SERVIER
  • Porton Biopharma Limited
  • Eli Lily and Company
  • Novo Nordisk A/S
  • Biogen Inc.
  • CSL Behring GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Celltrion Healthcare Co., Ltd.

Biobetters Market Research Segmentation:

The biobetters market encompasses a diverse range of products, technologies, therapeutic applications, and end-user segments, addressing various chronic and complex disease areas.

By Product Type

  • Erythropoietin Biobetters
  • G-CSF Biobetters
  • Interferon Biobetters
  • Insulin Biobetters
  • Monoclonal Antibodies Biobetters
  • Anti-haemophilic Factor
  • Others

By Indication

  • Diabetes
  • Cancer
  • Renal Disease
  • Neurodegenerative Disease
  • Genetic Disorders (Haemophilia)
  • Others

By Route of Administration

  • Subcutaneous
  • Intravenous

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • The Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Biobetters Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Biobetters Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Biobetters Market Outlook: Product Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
      • 4.3.3.1. Erythropoietin Biobetters
      • 4.3.3.2. G-CSF Biobetters
      • 4.3.3.3. Interferon Biobetters
      • 4.3.3.4. Insulin Biobetters
      • 4.3.3.5. Monoclonal Antibodies Biobetters
      • 4.3.3.6. Anti-haemophilic Factor
      • 4.3.3.7. Others
    • 4.3.4. Market Attractiveness Analysis: Product Type
  • 4.4. Global Biobetters Market Outlook: Indication
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
      • 4.4.3.1. Diabetes
      • 4.4.3.2. Cancer
      • 4.4.3.3. Renal Disease
      • 4.4.3.4. Neurodegenerative Disease
      • 4.4.3.5. Genetic Disorders (Haemophilia)
      • 4.4.3.6. Others
    • 4.4.4. Market Attractiveness Analysis: Indication
  • 4.5. Global Biobetters Market Outlook: Route of Administration
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
      • 4.5.3.1. Subcutaneous
      • 4.5.3.2. Intravenous
    • 4.5.4. Market Attractiveness Analysis: Route of Administration
  • 4.6. Global Biobetters Market Outlook: Distribution Channel
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
      • 4.6.3.1. Hospital Pharmacies
      • 4.6.3.2. Retail Pharmacies
      • 4.6.3.3. Online Pharmacies
    • 4.6.4. Market Attractiveness Analysis: Distribution Channel

5. Global Biobetters Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Biobetters Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product Type
    • 6.2.3. By Indication
    • 6.2.4. By Route of Administration
    • 6.2.5. By Distribution Channel
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 6.4.1. Erythropoietin Biobetters
    • 6.4.2. G-CSF Biobetters
    • 6.4.3. Interferon Biobetters
    • 6.4.4. Insulin Biobetters
    • 6.4.5. Monoclonal Antibodies Biobetters
    • 6.4.6. Anti-haemophilic Factor
    • 6.4.7. Others
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 6.5.1. Diabetes
    • 6.5.2. Cancer
    • 6.5.3. Renal Disease
    • 6.5.4. Neurodegenerative Disease
    • 6.5.5. Genetic Disorders (Haemophilia)
    • 6.5.6. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 6.6.1. Subcutaneous
    • 6.6.2. Intravenous
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 6.7.1. Hospital Pharmacies
    • 6.7.2. Retail Pharmacies
    • 6.7.3. Online Pharmacies
  • 6.8. Market Attractiveness Analysis

7. Europe Biobetters Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product Type
    • 7.2.3. By Indication
    • 7.2.4. By Route of Administration
    • 7.2.5. By Distribution Channel
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 7.4.1. Erythropoietin Biobetters
    • 7.4.2. G-CSF Biobetters
    • 7.4.3. Interferon Biobetters
    • 7.4.4. Insulin Biobetters
    • 7.4.5. Monoclonal Antibodies Biobetters
    • 7.4.6. Anti-haemophilic Factor
    • 7.4.7. Others
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 7.5.1. Diabetes
    • 7.5.2. Cancer
    • 7.5.3. Renal Disease
    • 7.5.4. Neurodegenerative Disease
    • 7.5.5. Genetic Disorders (Haemophilia)
    • 7.5.6. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 7.6.1. Subcutaneous
    • 7.6.2. Intravenous
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 7.7.1. Hospital Pharmacies
    • 7.7.2. Retail Pharmacies
    • 7.7.3. Online Pharmacies
  • 7.8. Market Attractiveness Analysis

8. East Asia Biobetters Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product Type
    • 8.2.3. By Indication
    • 8.2.4. By Route of Administration
    • 8.2.5. By Distribution Channel
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 8.4.1. Erythropoietin Biobetters
    • 8.4.2. G-CSF Biobetters
    • 8.4.3. Interferon Biobetters
    • 8.4.4. Insulin Biobetters
    • 8.4.5. Monoclonal Antibodies Biobetters
    • 8.4.6. Anti-haemophilic Factor
    • 8.4.7. Others
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 8.5.1. Diabetes
    • 8.5.2. Cancer
    • 8.5.3. Renal Disease
    • 8.5.4. Neurodegenerative Disease
    • 8.5.5. Genetic Disorders (Haemophilia)
    • 8.5.6. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 8.6.1. Subcutaneous
    • 8.6.2. Intravenous
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 8.7.1. Hospital Pharmacies
    • 8.7.2. Retail Pharmacies
    • 8.7.3. Online Pharmacies
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Biobetters Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product Type
    • 9.2.3. By Indication
    • 9.2.4. By Route of Administration
    • 9.2.5. By Distribution Channel
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 9.4.1. Erythropoietin Biobetters
    • 9.4.2. G-CSF Biobetters
    • 9.4.3. Interferon Biobetters
    • 9.4.4. Insulin Biobetters
    • 9.4.5. Monoclonal Antibodies Biobetters
    • 9.4.6. Anti-haemophilic Factor
    • 9.4.7. Others
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 9.5.1. Diabetes
    • 9.5.2. Cancer
    • 9.5.3. Renal Disease
    • 9.5.4. Neurodegenerative Disease
    • 9.5.5. Genetic Disorders (Haemophilia)
    • 9.5.6. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 9.6.1. Subcutaneous
    • 9.6.2. Intravenous
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 9.7.1. Hospital Pharmacies
    • 9.7.2. Retail Pharmacies
    • 9.7.3. Online Pharmacies
  • 9.8. Market Attractiveness Analysis

10. Latin America Biobetters Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product Type
    • 10.2.3. By Indication
    • 10.2.4. By Route of Administration
    • 10.2.5. By Distribution Channel
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 10.4.1. Erythropoietin Biobetters
    • 10.4.2. G-CSF Biobetters
    • 10.4.3. Interferon Biobetters
    • 10.4.4. Insulin Biobetters
    • 10.4.5. Monoclonal Antibodies Biobetters
    • 10.4.6. Anti-haemophilic Factor
    • 10.4.7. Others
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 10.5.1. Diabetes
    • 10.5.2. Cancer
    • 10.5.3. Renal Disease
    • 10.5.4. Neurodegenerative Disease
    • 10.5.5. Genetic Disorders (Haemophilia)
    • 10.5.6. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 10.6.1. Subcutaneous
    • 10.6.2. Intravenous
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 10.7.1. Hospital Pharmacies
    • 10.7.2. Retail Pharmacies
    • 10.7.3. Online Pharmacies
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Biobetters Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product Type
    • 11.2.3. By Indication
    • 11.2.4. By Route of Administration
    • 11.2.5. By Distribution Channel
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 11.4.1. Erythropoietin Biobetters
    • 11.4.2. G-CSF Biobetters
    • 11.4.3. Interferon Biobetters
    • 11.4.4. Insulin Biobetters
    • 11.4.5. Monoclonal Antibodies Biobetters
    • 11.4.6. Anti-haemophilic Factor
    • 11.4.7. Others
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 11.5.1. Diabetes
    • 11.5.2. Cancer
    • 11.5.3. Renal Disease
    • 11.5.4. Neurodegenerative Disease
    • 11.5.5. Genetic Disorders (Haemophilia)
    • 11.5.6. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 11.6.1. Subcutaneous
    • 11.6.2. Intravenous
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 11.7.1. Hospital Pharmacies
    • 11.7.2. Retail Pharmacies
    • 11.7.3. Online Pharmacies
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Amgen Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. F.Hoffmann-La Roche AG
    • 12.3.3. Merck & Co. Inc.
    • 12.3.4. Sanofi SA
    • 12.3.5. SERVIER
    • 12.3.6. Porton Biopharma Limited
    • 12.3.7. Eli Lily and Company
    • 12.3.8. Novo Nordisk A/S
    • 12.3.9. Biogen Inc.
    • 12.3.10. CSL Behring GmbH
    • 12.3.11. Teva Pharmaceutical Industries Ltd.
    • 12.3.12. Celltrion Healthcare Co., Ltd.

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations